Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in 10x Genomics $TXG

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of 10x Genomics (NASDAQ:TXG) in the third quarter, HoldingsChannel.com reports. The firm bought 100,882 shares of the company’s stock, valued at approximately $1,179,000.

Several other hedge funds and other institutional investors have also bought and sold shares of TXG. Allworth Financial LP raised its position in shares of 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after acquiring an additional 1,364 shares in the last quarter. True Wealth Design LLC lifted its position in shares of 10x Genomics by 1,552.5% during the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after buying an additional 3,369 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of 10x Genomics by 48.1% in the 2nd quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock valued at $57,000 after buying an additional 1,590 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after buying an additional 5,025 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of 10x Genomics by 73.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,951 shares of the company’s stock worth $104,000 after buying an additional 3,801 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on TXG. TD Cowen reissued a “hold” rating on shares of 10x Genomics in a research report on Wednesday, January 7th. JPMorgan Chase & Co. upped their price target on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Wall Street Zen downgraded 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Canaccord Genuity Group increased their price target on 10x Genomics from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $16.83.

Insider Buying and Selling

In other news, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the sale, the insider owned 432,605 shares in the company, valued at $8,219,495. This represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the transaction, the chief executive officer directly owned 1,021,556 shares of the company’s stock, valued at approximately $19,409,564. This trade represents a 1.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 33,432 shares of company stock worth $635,208. 9.39% of the stock is owned by company insiders.

10x Genomics Price Performance

NASDAQ TXG opened at $20.20 on Friday. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -32.58 and a beta of 2.18. The stock’s fifty day moving average price is $18.64 and its 200 day moving average price is $15.22. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $23.56.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. The business had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.30) EPS. Research analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.